NATCOPHARM.NS
NATCO Pharma LimitedExplain this page
Arphra AIPlain-English read on NATCO Pharma Limited’s valuationRatios & metrics
Profitability, returns on capital, growth, and credit — all derived from the historical income statement, balance sheet, and cash flow rows in our data warehouse.
A snapshot of the latest fiscal year’s margins, returns on capital, balance-sheet strength and efficiency, computed from the income statement, balance sheet and cash-flow rows. Source income / balance / cash_flow.
Valuation multiples
| In USD | FY 2026 |
|---|---|
| Headline | |
| Market cap | $179.42B |
| Enterprise value | $184.57B |
| Multiples | |
| P / E | — |
| P / B | — |
| EV / EBITDA | — |
| EV / Sales | 4.53 |
| EV / FCF | 13.40 |
| Yields | |
| Earnings yield | +7.91% |
| Free cash flow yield | +7.68% |
| Dividend yield | — |
Profitability
| In USD | FY 2026 |
|---|---|
| Margins | |
| Gross margin | +83.07% |
| Operating margin | +30.16% |
| EBITDA margin | +42.52% |
| EBIT margin | +37.45% |
| Pre-tax margin | +37.70% |
| Net margin | +34.78% |
| Cost structure | |
| Cost of revenue / sales | +16.93% |
| R&D intensity | 0.00% |
| SG&A intensity | 0.00% |
| Effective tax rate | +7.73% |
Returns on capital
| In USD | FY 2026 |
|---|---|
| Returns | |
| Return on equity (ROE) | +15.38% |
| Return on assets (ROA) | +12.81% |
| Return on capital (ROC) | +12.38% |
| Return on invested capital (ROIC) | +14.28% |
| Asset turnover | +36.83% |
| DuPont · ROE decomposition | |
| Net margin | +34.78% |
| Asset turnover (× revenue / assets) | +36.83% |
| Equity multiplier (× assets / equity) | +120.09% |
Activity & efficiency
| In USD | FY 2026 |
|---|---|
| Turnover | |
| Asset turnover | 0.37 |
| Fixed-asset turnover | 1.44 |
| Inventory turnover | 0.76 |
| Receivables turnover | 4.58 |
| Payables turnover | 1.69 |
| Days outstanding | |
| Days sales outstanding (DSO) | 79.74 |
| Days inventory outstanding (DIO) | 480.24 |
| Days payables outstanding (DPO) | 216.36 |
| Cash conversion cycle | 343.62 |
Cash flow quality
| In USD | FY 2026 |
|---|---|
| Operating CF / Net income | 1.25 |
| FCF / Net income | 0.97 |
| FCF margin | +33.77% |
| OCF margin | +43.36% |
| CapEx / Revenue | +9.59% |
| CapEx / D&A | 1.89 |
| Stock-based comp / Revenue | 0.00% |
Per-share & shareholder yield
| In USD | FY 2026 |
|---|---|
| EPS · diluted | 79.21 |
| EPS · basic | 79.21 |
| Book value / share | 514.92 |
| Tangible BV / share | 500.55 |
| Sales / share | 227.74 |
| Operating CF / share | 98.74 |
| Free cash flow / share | 76.91 |
| Dividends / share | 5.04 |
| Payout ratio | +6.36% |
| Retention ratio | +93.64% |
Growth
| In USD | FY 2026 | CAGR |
|---|---|---|
| Top-line | ||
| Revenue · YoY | — | — |
| Gross profit · YoY | — | — |
| Profit | ||
| Operating income · YoY | — | — |
| EBITDA · YoY | — | — |
| Net income · YoY | — | — |
| Operating | ||
| EBIT · YoY | — | — |
| R&D · YoY | — | — |
| Per-share | ||
| EPS · diluted · YoY | — | — |
| EPS · basic · YoY | — | — |
Credit & leverage
| In USD | FY 2026 |
|---|---|
| Leverage | |
| Total debt | $7.14B |
| Net debt | $5.15B |
| Net debt / EBITDA | 0.30 |
| Debt / equity | 0.08 |
| Debt / assets | +6.45% |
| Equity / assets | +83.27% |
| Coverage | |
| EBITDA / interest expense | 47.25 |
| Operating income / interest | 33.51 |
| Interest expense | $367M |
| Liquidity | |
| Current ratio | 3.01 |
| Quick ratio | 2.24 |
| Cash ratio | 0.12 |
| Working capital | $33.71B |
| Working capital / revenue | +82.67% |
Historical multiples · μ ± σ bands
3 fiscal-year-end observations from key_metrics. Mean is dashed; light-green band is ±1σ, light-red band ±2σ. The dot marks the most recent value; the cheap / fair / rich verdict uses z-score against the issuer's own history (yields inverted — a high yield is cheap).
Sourced from key_metrics + financial_ratios (loaded by load_fundamentals_extended.py).
| Metric | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| P / E | — | — | — |
| P / B | — | — | — |
| EV / EBITDA | — | — | — |
| EV / Sales | 4.53x | 2.83x | 4.45x |
| Earnings yield | 7.9% | 13.1% | 7.9% |
| FCF yield | 7.7% | 9.9% | 5.0% |
| Metric | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Gross margin | — | — | — |
| Operating margin | — | — | — |
| Net margin | — | — | — |
| ROE | 15.4% | 24.8% | 23.7% |
| ROA | 12.8% | 21.8% | 20.1% |
| ROIC | 11.3% | 31.0% | 34.1% |
| Metric | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Debt / equity | — | — | — |
| Net debt / EBITDA | 0.30 | -0.88 | 0.18 |
| Interest coverage | — | — | — |
| Current ratio | 3.01x | 5.59x | 4.14x |
| Quick ratio | — | — | — |
Methodology. ROE / ROA / ROC use period-end balance-sheet denominators (no average-of- period smoothing). ROIC = Operating Income × (1 − inferred effective tax rate) over invested capital, with the effective tax inferred from net-to-operating income when both are positive and a 25% default otherwise. Net debt / EBITDA, debt ratios, and interest-coverage ratios are calculated point-in-time at each fiscal year-end. TTM = trailing 4 quarters (income / cash flow summed, balance sheet = most-recent quarterly snapshot). Through-cycle CAGR in the Growth panel uses the geometric mean of first-to-last period growth across the window (positive values only).